Glaukos Co. (NYSE:GKOS) Stake Boosted by Assenagon Asset Management S.A.

Assenagon Asset Management S.A. lifted its holdings in Glaukos Co. (NYSE:GKOS - Free Report) by 31.3% during the third quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 75,798 shares of the medical instruments supplier's stock after buying an additional 18,067 shares during the quarter. Assenagon Asset Management S.A. owned 0.15% of Glaukos worth $9,875,000 as of its most recent SEC filing.

A number of other institutional investors and hedge funds have also recently bought and sold shares of the business. Vanguard Group Inc. boosted its stake in shares of Glaukos by 1.4% during the 1st quarter. Vanguard Group Inc. now owns 5,308,897 shares of the medical instruments supplier's stock worth $500,576,000 after acquiring an additional 72,159 shares in the last quarter. Fred Alger Management LLC boosted its position in Glaukos by 3.8% during the second quarter. Fred Alger Management LLC now owns 1,278,723 shares of the medical instruments supplier's stock worth $151,337,000 after purchasing an additional 47,308 shares in the last quarter. Primecap Management Co. CA grew its holdings in Glaukos by 43.9% in the second quarter. Primecap Management Co. CA now owns 1,220,815 shares of the medical instruments supplier's stock valued at $144,483,000 after purchasing an additional 372,180 shares during the last quarter. Driehaus Capital Management LLC grew its holdings in Glaukos by 24.0% in the second quarter. Driehaus Capital Management LLC now owns 803,650 shares of the medical instruments supplier's stock valued at $95,112,000 after purchasing an additional 155,653 shares during the last quarter. Finally, Point72 Asset Management L.P. purchased a new position in shares of Glaukos in the second quarter valued at $67,460,000. Institutional investors and hedge funds own 99.04% of the company's stock.

Wall Street Analysts Forecast Growth

A number of brokerages recently commented on GKOS. StockNews.com raised shares of Glaukos from a "sell" rating to a "hold" rating in a research note on Monday, October 21st. Needham & Company LLC upped their price objective on shares of Glaukos from $131.00 to $137.00 and gave the company a "buy" rating in a research note on Thursday, August 1st. Truist Financial lifted their target price on shares of Glaukos from $145.00 to $152.00 and gave the stock a "buy" rating in a research note on Monday, October 14th. Morgan Stanley increased their price target on Glaukos from $100.00 to $120.00 and gave the stock an "equal weight" rating in a research note on Monday, July 15th. Finally, Wells Fargo & Company lifted their price objective on Glaukos from $120.00 to $135.00 and gave the company an "overweight" rating in a research report on Thursday, August 1st. Four investment analysts have rated the stock with a hold rating and eight have given a buy rating to the stock. According to MarketBeat, the company presently has a consensus rating of "Moderate Buy" and a consensus price target of $130.45.

Insider Activity at Glaukos

In other Glaukos news, Director Aimee S. Weisner sold 25,000 shares of the company's stock in a transaction that occurred on Thursday, August 8th. The stock was sold at an average price of $120.00, for a total value of $3,000,000.00. Following the transaction, the director now directly owns 30,119 shares of the company's stock, valued at $3,614,280. This represents a 0.00 % decrease in their position. The sale was disclosed in a document filed with the SEC, which is available at the SEC website. In other news, Director Aimee S. Weisner sold 25,000 shares of Glaukos stock in a transaction on Thursday, August 8th. The stock was sold at an average price of $120.00, for a total transaction of $3,000,000.00. Following the transaction, the director now directly owns 30,119 shares in the company, valued at approximately $3,614,280. This trade represents a 0.00 % decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Also, Director Gilbert H. Kliman sold 3,000 shares of Glaukos stock in a transaction dated Monday, September 9th. The stock was sold at an average price of $130.67, for a total value of $392,010.00. Following the transaction, the director now directly owns 32,336 shares in the company, valued at approximately $4,225,345.12. The trade was a 0.00 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last 90 days, insiders sold 39,250 shares of company stock valued at $4,825,873. Insiders own 6.40% of the company's stock.

Glaukos Stock Up 2.7 %

NYSE:GKOS traded up $3.49 during trading hours on Monday, hitting $134.08. The stock had a trading volume of 471,028 shares, compared to its average volume of 569,984. The company has a market cap of $6.75 billion, a PE ratio of -46.56 and a beta of 1.02. The business has a 50 day simple moving average of $129.22 and a two-hundred day simple moving average of $118.66. Glaukos Co. has a 1-year low of $59.22 and a 1-year high of $136.60. The company has a current ratio of 5.48, a quick ratio of 4.67 and a debt-to-equity ratio of 0.19.

Glaukos (NYSE:GKOS - Get Free Report) last released its quarterly earnings results on Wednesday, July 31st. The medical instruments supplier reported ($0.52) earnings per share (EPS) for the quarter, hitting the consensus estimate of ($0.52). The firm had revenue of $95.70 million for the quarter, compared to the consensus estimate of $88.86 million. Glaukos had a negative net margin of 47.39% and a negative return on equity of 22.51%. The firm's quarterly revenue was up 19.0% on a year-over-year basis. During the same quarter in the previous year, the firm posted ($0.55) EPS. Analysts predict that Glaukos Co. will post -2.16 EPS for the current year.

Glaukos Profile

Glaukos Corporation, an ophthalmic pharmaceutical and medical technology company, focuses on the development of novel therapies for the treatment of glaucoma, corneal disorders, and retinal diseases. It offers iStent and iStent inject W micro-bypass stents that enhance aqueous humor outflow inserted in cataract surgery to treat mild-to-moderate open-angle glaucoma.